Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Rodriguez 2025 (EHR, n=125,474): 1-year discontinuation 64.8% in non-diabetics vs 46.5% in type 2 diabetes
Key Research Features Dual-mechanism research blend angiogenic + cytoskeletal pathways BPC-157: VEGF/VEGFR2-Akt-eNOS axis and NO system modulation TB-500: actin sequestration and G-actin/F-actin polymerization balance Precision co-lyophilized 1:1 ratio minimizes preparation variability 20mg total content suited for high-throughput and extended protocols 99% HPLC-verified purity per component Lyophilized powder format Suitable for in vitro and preclinical research Batch-tested for consistency Research-grade manufacturing standards Professionally labeled and documented Storage Recommendations To maintain product stability and research integrity, BPC-157 / TB-500 should be: Stored at 20C in a tightly sealed container Reconstituted with sterile bacteriostatic water, added slowly along the vial wall with gentle swirling avoid vigorous shaking Protected from light and moisture Kept sealed until use Handled according to standard laboratory procedures Not subjected to repeated freeze-thaw cycles Toxicology and Regulatory Information BPC-157 evaluated in preclinical toxicology research models BPC-157 listed by the U.S
TB-500 TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (T4), an endogenous protein known to be upregulated in response to tissue injury
They show promising results in animal studies, but human evidence is limited, so we cannot confirm real clinical benefit
